These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 35412132

  • 1. Peptide-Based HIV Entry Inhibitors.
    Pu J, Wang Q, Jiang S.
    Adv Exp Med Biol; 2022; 1366():15-26. PubMed ID: 35412132
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. HIV entry inhibitors: progress in development and application.
    Lai WH, Huang L, Chen CH.
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [Abstract] [Full Text] [Related]

  • 4. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E, Becić F, Zvizdić S.
    Med Arh; 2005 Feb; 59(5):313-6. PubMed ID: 16134757
    [Abstract] [Full Text] [Related]

  • 5. Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41.
    Pu J, Wang Q, Xu W, Lu L, Jiang S.
    Viruses; 2019 Aug 01; 11(8):. PubMed ID: 31374953
    [Abstract] [Full Text] [Related]

  • 6. HIV entry and fusion inhibitors.
    Chantry D.
    Expert Opin Emerg Drugs; 2004 May 01; 9(1):1-7. PubMed ID: 15155132
    [Abstract] [Full Text] [Related]

  • 7. Entry inhibitors in the treatment of HIV-1 infection.
    Tilton JC, Doms RW.
    Antiviral Res; 2010 Jan 01; 85(1):91-100. PubMed ID: 19683546
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.
    J Virol; 2019 Jun 01; 93(11):. PubMed ID: 30867304
    [Abstract] [Full Text] [Related]

  • 10. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E, Porichis F, Spandidos DA.
    Acta Pharmacol Sin; 2005 Oct 01; 26(10):1165-73. PubMed ID: 16174430
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML, Cammack N.
    J Antimicrob Chemother; 2004 Aug 01; 54(2):333-40. PubMed ID: 15231762
    [Abstract] [Full Text] [Related]

  • 14. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S, Zhao Q, Debnath AK.
    Curr Pharm Des; 2002 Aug 01; 8(8):563-80. PubMed ID: 11945159
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enfuvirtide.
    Lalezari JP, Luber AD.
    Drugs Today (Barc); 2004 Mar 01; 40(3):259-69. PubMed ID: 15148534
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Inhibitors of fusion: a new alternative in the treatment of HIV infection].
    Roca Villanueva B.
    Med Clin (Barc); 2004 May 08; 122(17):659-60. PubMed ID: 15153345
    [No Abstract] [Full Text] [Related]

  • 19. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
    Gómara MJ, Haro I.
    Curr Med Chem; 2014 Apr 08; 21(10):1188-200. PubMed ID: 23931277
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.